Insulet’s (Nasdaq:PODD) stock soared more than 20% today on first-quarter results that exceeded the consensus forecast.
Shares of PODD were trading at around $307 a share near the close of trading, the day after the company’s evening earnings report.
The Acton, Massachusetts–based automated insulin delivery technology maker reported profits of $35.4 million. That equals 50¢ per share on sales of $569 million for the three months ended March 31, 2025.
Insulet recorded a 31.3% bottom-line slide on a sales increase of 28.8%.
Adjusted to exclude one-time items, earnings per share came in at $1.02. That landed 23¢ ahead of expectations on Wall Street. Sales also topped estimates as experts forecast $543.3 million.
“Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet’s new president and CEO, I see a path to scale the company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our podders,” said Ashley McEvoy, president and CEO.
